Effect of verapamil on the pharmacokinetics of pasireotide in healthy volunteers.
We evaluated the drug-drug interaction between pasireotide SC and verapamil, a known P-glycoprotein inhibitor. Subjects received pasireotide SC (single dose, 600 μg) on day 1, and samples for pharmacokinetics evaluation were collected from days 1 to 8. Subjects received an oral dose of verapamil 240 mg/d for 10 days (days 15-24). On day 18, subjects also received pasireotide SC 600 μg. Pharmacokinetic sampling for pasireotide SC and verapamil was done during days 18 to 25 and days 15 to 21, respectively. Safety evaluations were performed throughout the study period, including a 30-day post-treatment follow-up. Pharmacokinetic profiles of pasireotide SC alone and in combination with verapamil sustained-release (SR) were superimposable with the geometric mean ratios (90% confidence interval [CI]) of 0.98 (0.91-1.06) for C(max), 0.97 (0.90-1.04) for AUC(last), and 0.98 (0.92-1.05) for AUC(inf). Exploratory analyses showed a 17% (90% CI, 0.72-0.94) reduction in C(trough) and 31% (0.58-0.82) reduction in C(max) (8 hours post-dose) for verapamil SR with pasireotide SC versus verapamil alone. Pasireotide SC with or without verapamil was well tolerated. In conclusion, there was no change in the rate of pasireotide absorption and elimination or extent of exposure following concomitant administration with verapamil.
Parexel International GmbH, Berlin, Germany.
Ruediger
R
Kornberger
Lillian S L
LS
Ting
Anadya P
AP
Tripathi
Heidi
H
Rodrigues
Dalal
D
Nesheiwat
Vanessa Q
VQ
Passos
Ke
K
Hu
D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004347:Drug Interactions; D006801:Humans; D008297:Male; D008875:Middle Aged; D013004:Somatostatin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D014700:Verapamil / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*
D000889:Anti-Arrhythmia Agents; D018931:Antineoplastic Agents, Hormonal; D013004:Somatostatin; C517782:pasireotide; D014700:Verapamil
P-gp inhibitor; drug-drug interaction; pasireotide; pharmacokinetics; verapamil